SELLAS Life Sciences Group (NASDAQ:SLS) Issues Quarterly Earnings Results

SELLAS Life Sciences Group (NASDAQ:SLS) issued its earnings results on Thursday. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.03, Zacks reports.

SELLAS Life Sciences Group Price Performance

SELLAS Life Sciences Group stock remained flat at $1.21 during mid-day trading on Thursday. 535,015 shares of the company’s stock were exchanged, compared to its average volume of 1,414,350. SELLAS Life Sciences Group has a fifty-two week low of $0.77 and a fifty-two week high of $1.84. The stock’s 50-day moving average price is $1.20 and its 200 day moving average price is $1.17. The stock has a market capitalization of $85.16 million, a price-to-earnings ratio of -1.75 and a beta of 2.43.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc, a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.